In this Article, Haitang Yang is incorrectly listed as being affiliated with the ‘Department of Pathology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 230032, China’. The correct affiliation is listed below:
Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 230032, China.
Additional information
The online version of the original article can be found at 10.1038/srep36371
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Xu, J., Yang, H., Jin, B. et al. Correction: Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation. Sci Rep 6, 38270 (2016). https://doi.org/10.1038/srep38270
Published:
DOI: https://doi.org/10.1038/srep38270
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
